5243722025-04-012025-06-305243722025-06-305243722025-04-012025-06-30in-capmkt:OtherExpenses1Member5243722025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722025-06-30Statement15243722025-04-012025-06-30Statement15243722025-06-30StatementDynamic1I1Statement15243722025-06-30StatementDynamic1I2Statement15243722025-06-30StatementDynamic1I3Statement15243722025-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027Orchid Pharma LimitedMain BoardEquity2025-04-012026-03-312025-08-122025-08-05INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical2025-08-1212:00:002025-08-1215:30:00Not applicabletrue1falseNot Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period. <BR> <BR> Also, the Company has not raised funds during the quarter but due to the mandatory requirement in technical point of this utility at Row No. 42 of this page is selected as 1. 2025-04-012025-06-30UnauditedStandalone1729288000159304000188859200011015740007879000-12079900021612900032575000865410003827190001706618000181974000018197400000001819740000000181974000-1548000180426000507191000103.593.59003.593.591. The above results for the quarter and year ended June 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 12, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. <BR> 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <BR> 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. <BR> As on June 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <BR> Statement of QIP Net Funds raised and utilisation <BR> Particulars Amount as stated in Total amount utilised Balance amount as on Remarks <BR> the Offer Document upto June 30, 2025 on June 30, 2025 kept <BR> Rs. In Lakhs Rs. In Lakhs in Fixed Deposits Rs.in lakhs <BR> 1. Investment in OBPL, <BR> subsidiary, for setting up <BR> Jammu Manufacturing Facility 9000 6461 2539 <BR> 2. Repayment/prepayment, in <BR> full or in part, of certain <BR> outstanding borrowings <BR> availed by the company 14100 14100 - <BR> 3. Funding capital expenditure <BR> requirements for setting up a <BR> new block at the API facility <BR> of the Company in Alathur, <BR> Tamil Nadu 9982 36 9946 <BR> 4. General corporate purposes 6098 6372 0 <BR> Total 39180 26969 12485 <BR> <BR> As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on June 30, 2025. <BR> Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. <BR> <BR> 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. <BR> 5. The figures for the quarters ended 31 March, 2025 represents the balancing figures between audited results for the year ended March 31, 2025 and the published year to date figures up to the third quarter of the relevant year. <BR> 6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the <BR> Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, <BR> in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, <BR> giving No objection to the said amalgamation. <BR> The Honourable NCLT vide its order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed with the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. Subsequently, the requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, pursuant to which the Honourable NCLT admitted the petion for its consideration and sanction. <BR> <BR> 7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.Other expenses382719000Items that will not be reclassified to profit and loss-1548000-154800000-1548000QIP2023-06-2740000000002025-06-30trueCare Ratings LimitedfalseRemark 1 Delay in implementation of the object(s) w.r.t the object- Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu but the extent of delay is not ascertainable. Comment Alathur project is for further processing of proposed 7ACA into intermediate goods or downstream products from Jammu Project. The Land acquisition for setting up 7ACA project at Jammu is delayed. Consequently, there is delay in setting up of API Facility at Alathur. Hence the major amount remained unutilised. Remark 2 Delay in implementation of the object(s) w.r.t the object- Investment in OBPL for setting up Jammu Manufacturing Facility but the extent of delay is not ascertainable. Comment The Land of around 203.8 Kanal (25.475 acres) at Jammu had been identified, out of which registration of 158.30 Kanal (19.79 acres) of land has completed and registration of the remaining land parcel is expect to be completed before October 2025. Bhoomi Pooja for the project was successfully performed on September 07, 2024. Construction of boundary and building work had been already started. Purchase orders for major equipments have also been placed and delivery of equipments at site will start shortly. The Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) or registration was required. This has led to delay in acquiring land.Kapil DayyaCompany Secretary and Compliance OfficerGurugram2025-08-12Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in JammuNot Applicable90000000006461000000Monitoring Agency in its Report dated August 04, 2025 had comments that The company has transferred Rs 20.45 crores from MA account to CC account as reimbursement of investment already made in OBPL from its own sources.Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our CompanyNot Applicable1410000000014100000000Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil NaduNot Applicable998200000036000000General Corporate PurposesNot Applicable60980000006372000000As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs.